Patients with ET experience diagnostic delays, averaging 26.5 months from the first elevated platelet count to diagnosis, indicating potential underestimation of the disease's burden. The study ...
Essential thrombocythemia is a chronic condition with excessive platelet production, increasing thrombosis risk, and is often linked to JAK2, CALR, or MPL mutations. Stage 1 ET is manageable with ...
Phase 2 trial data have shown that the CD38-targeting antibody mezagitamab can rapidly restore platelet counts in immune thrombocytopenia, with strong response rates at higher doses and a safety ...
Essential thrombocythemia (ET) is a type of myeloproliferative neoplasm (MPN), a rare blood disorder that causes an increase in the number of blood cells. Some symptoms include headaches, dizziness, ...
Abstract and Introduction Review of Normal Platelet Physiology and Megakaryocytopoisis Qualitative Platelet Abnormalities Conclusion References Nitric oxide (NO) is another drug used in the neonatal ...
The anti-CD38 monoclonal antibody mezagitamab had similar safety to placebo in patients with persistent or chronic immune thrombocytopenia. The drug also significantly increased platelet counts, a key ...
Daratumumab produced rapid and sustained platelet responses in adults with immune thrombocytopenia (ITP), according to a recent single-center, open-label, phase 2 clinical trial (NCT05562882). Despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results